Compositions and methods for viral sensitization
US-2024360115-A1 · Oct 31, 2024 · US
Enterococcus faecium bacteriophage Ent-FAP-4 and use for inhibiting Enterococcus faecium proliferation of same
US11458177B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11458177-B2 |
| Application number | US-201816487506-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 11, 2018 |
| Priority date | Feb 22, 2017 |
| Publication date | Oct 4, 2022 |
| Grant date | Oct 4, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to Siphoviridae bacteriophage Ent-FAP-4 (accession number KCTC 12854BP), separated from nature, which is capable of specifically killing Enterococcus faecium and has a genome expressed by sequence number 1, a pharmaceutical composition, which comprises same as an active ingredient, and a method for preventing or treating diseases, induced by Enterococcus faecium, by administering the pharmaceutical composition.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of suppressing diseases caused by a bacterial strain of Enterococcus faecium and alleviating pathological condition of the diseases caused by the bacterial strain of Enterococcus faecium, comprising: administering to an animal other than a human a composition comprising Siphoviridae bacteriophage Ent-FAP-4 which has an ability to specifically kill the bacterial strain of Enterococcus faecium and has the genome represented by the nucleic acid sequence of SEQ ID NO: 1, and is deposited as the accession number of KCTC 12854BP, wherein the diseases are urinary tract infections, wound infections, bacteremia or endocarditis.
Assignees
Inventors
Classifications
Viruses as such, e.g. new isolates, mutants or their genomic sequences · CPC title
- C12N7/00Primary
Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title
- A61K35/76Primary
Viruses; Subviral particles; Bacteriophages · CPC title
Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11458177B2 cover?
- The present invention relates to Siphoviridae bacteriophage Ent-FAP-4 (accession number KCTC 12854BP), separated from nature, which is capable of specifically killing Enterococcus faecium and has a genome expressed by sequence number 1, a pharmaceutical composition, which comprises same as an active ingredient, and a method for preventing or treating diseases, induced by Enterococcus faecium, b…
- Who is the assignee on this patent?
- Intron Biotechnology Inc
- What technology area does this patent fall under?
- Primary CPC classification C12N7/00. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Oct 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).